Announcement • Jun 04
Agfa-Gevaert Appoints Mark Pensaert as an Independent Director Agfa-Gevaert announced that its Board of Directors had confirmed the effectiveness of the resignation of Mr. Michel Govaert (permanent representative of MJP Management Services BV) as Independent Director. The Board co-opted MRP Consulting BV, represented by Mr. Mark Pensaert, as an Independent Director of the Company, thus ensuring that the Board continuously meets the statutory requirement of having at least 6 members. Mr. Pensaert previously already served as an Independent Director from May 2018 until the Annual General Meeting in May 2026. During this interim period, Mr. Pensaert will also continue to serve as Chair of the Audit Committee. Announcement • May 22
Agfa-Gevaert Announces Resignation of Michel Govaert from the Board of Directors, Effective May 20, 2026 Agfa-Gevaert announced that Mr. Michel Govaert (as permanent representative of MJP Management Services BV) has decided for personal reasons to tender his resignation as Independent Board Member, with effect from May 20, 2026. The procedure for his succession will be started shortly by the Nomination & Remuneration Committee. Reported Earnings • May 14
First quarter 2026 earnings released: €0.047 loss per share (vs €0.14 loss in 1Q 2025) First quarter 2026 results: €0.047 loss per share (improved from €0.14 loss in 1Q 2025). Revenue: €236.0m (down 2.5% from 1Q 2025). Net loss: €7.00m (loss narrowed 67% from 1Q 2025). Revenue is forecast to stay flat during the next 3 years compared to a 12% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has fallen by 43% per year, which means it is significantly lagging earnings. Announcement • May 14
Agfa-Gevaert NV Approves Appointment of Géraldine Nolen as Independent Director Agfa-Gevaert NV announced at annual general meeting held on May 12, 2026, the shareholders voted in favor of the appointment of inGENuity BV, permanently represented by Mrs. Géraldine Nolens, as independent director of the Company for a four year period. Announcement • Apr 13
Agfa-Gevaert NV, Annual General Meeting, Jun 12, 2026 Agfa-Gevaert NV, Annual General Meeting, Jun 12, 2026, at 11:00 Romance Standard Time. Reported Earnings • Apr 12
Full year 2025 earnings released: €0.41 loss per share (vs €0.59 loss in FY 2024) Full year 2025 results: €0.41 loss per share (improved from €0.59 loss in FY 2024). Revenue: €1.09b (down 4.6% from FY 2024). Net loss: €63.0m (loss narrowed 31% from FY 2024). Revenue is forecast to stay flat during the next 3 years compared to a 13% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 51% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings. Announcement • Mar 11
Agfa-Gevaert NV Reports Impairment Charges for the Fourth Quarter Ended December 31, 2025 Agfa-Gevaert NV reported Impairment charges for the fourth quarter ended December 31, 2025. For the quarter, the company reported Impairment losses on goodwill, intangibles and PP&E of €22 million against €20 million a year ago. New Risk • Mar 02
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €70m Forecast net loss in 2 years: €5.2m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€5.2m net loss in 2 years). Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (€74.3m market cap, or US$87.2m). Announcement • Dec 18
Agfa-Gevaert NV to Report Fiscal Year 2025 Final Results on Apr 10, 2026 Agfa-Gevaert NV announced that they will report fiscal year 2025 final results at 9:00 AM, Central European Standard Time on Apr 10, 2026 New Risk • Dec 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (€74.2m market cap, or US$86.4m). New Risk • Dec 05
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €85.2m (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. This is currently the only risk that has been identified for the company. Reported Earnings • Nov 19
Third quarter 2025 earnings released: €0.11 loss per share (vs €0.08 loss in 3Q 2024) Third quarter 2025 results: €0.11 loss per share (further deteriorated from €0.08 loss in 3Q 2024). Revenue: €257.0m (down 7.2% from 3Q 2024). Net loss: €18.0m (loss widened 39% from 3Q 2024). Revenue is expected to decline by 8.4% p.a. on average during the next 3 years, while revenues in the Healthcare Services industry in Europe are expected to grow by 12%. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 40% per year, which means it is significantly lagging earnings. New Risk • Nov 18
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €64m Forecast net loss in 2 years: €2.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Reported Earnings • Aug 31
Second quarter 2025 earnings released Second quarter 2025 results: EPS: €0.20. Revenue: €281.0m (down 1.7% from 2Q 2024). Net income: €31.0m (up €31.0m from 2Q 2024). Profit margin: 11% (up from 0% in 2Q 2024). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings. Board Change • Jun 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 1 highly experienced director. Independent Director Michel Govaert was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • May 16
First quarter 2025 earnings released: €0.14 loss per share (vs €0.11 loss in 1Q 2024) First quarter 2025 results: €0.14 loss per share (further deteriorated from €0.11 loss in 1Q 2024). Revenue: €242.0m (down 3.2% from 1Q 2024). Net loss: €21.0m (loss widened 31% from 1Q 2024). Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Healthcare Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Announcement • Apr 14
Agfa-Gevaert NV, Annual General Meeting, May 13, 2025 Agfa-Gevaert NV, Annual General Meeting, May 13, 2025, at 11:00 Romance Standard Time. Announcement • Mar 01
Agfa Approves the Appoints Michel Govaert as Independent Director for A Period of 4 Years Agfa at the Special General Meeting held on February 28, 2025, approved the appointment of MJP Management Services BV, with permanent representative Mr. Michel Govaert, as independent director for a period of 4 years. Announcement • Nov 20
Agfa Introduces Glass-Free Dura-Line DR Detectors at RSNA 2024, Delivering Superior Durability and Ultra-High Resolution Agfa is expanding its Dura-line family of robust, reliable and cost-effective wireless Digital Radiography (DR) flat panel detectors, with the glass-free and high-resolution Dura-line XF+ range, which comes in three sizes. At RSNA 2024, Agfa will demonstrate how the XF+ 10, XF+ 14, XF+ 17 detectors deliver exquisite image quality, low weight and high durability. Dura-line Cesium Iodide detectors offer robust reliability, cost-effectiveness, the potential for significant patient dose reduction[1] and outstanding 15-hour battery autonomy. The panels can be shared between different modalities, thanks to the Near-Field Communication (NFC) technology. The Dura-line XF+ range is built to withstand the toughest conditions and busiest hospital environments, drops from heights of up to 1.5 meters, as well as water and dust ingress protection. Designed to enhance workflow and operator comfort, the lightweight construction further improves operator ergonomics. The ultra-high resolution and high detector quantum efficiency (DQE) of Dura-line XF+ detectors, combined with Agfa's MUSICA image processing, ensure excellent contrast and consistent image quality across various exams. XF+ is supporting semi-dynamic mode for tomosynthesis. The SmartXR portfolio adds X-ray intelligence to predictive workflow assistance, for improved productivity and consistent outcomes. Visit us at RNSA 2024 to discover how Agfa's innovative Dura-line XF+ range delivers superior image quality, ergonomic design, and enhanced durability: Chicago, Il., from December 1-4, booth #2565 in the South Hall. New Risk • Nov 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (€92.3m market cap, or US$97.8m). Reported Earnings • Nov 17
Third quarter 2024 earnings released: €0.08 loss per share (vs €0.08 loss in 3Q 2023) Third quarter 2024 results: €0.08 loss per share (in line with 3Q 2023). Revenue: €277.0m (down 1.1% from 3Q 2023). Net loss: €13.0m (loss widened 8.3% from 3Q 2023). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 7.3% growth forecast for the Healthcare Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 41% per year, which means it is performing significantly worse than earnings. Breakeven Date Change • Aug 30 The 3 analysts covering Agfa-Gevaert previously expected the company to break even in 2025. New consensus forecast suggests losses will reduce by 51% to 2024. The company is expected to make a profit of €8.00m in 2025. Average annual earnings growth of 107% is required to achieve expected profit on schedule.
Reported Earnings • Aug 30
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: €286.0m (flat on 2Q 2023). Net income: €0 (up €17.0m from 2Q 2023). Profit margin: 0% (up from net loss in 2Q 2023). Revenue is forecast to grow 4.7% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 31% per year whereas the company’s share price has fallen by 35% per year. Announcement • Aug 28
Agfa-Gevaert NV Provides Earnings Guidance for the Year 2024 Agfa-Gevaert NV provided earnings guidance for the year 2024. In 2024, the company expects a continuation of the trends seen in the previous year, with continued growth and further profitability improvements for the growth engines. The weakness in Radiology Solutions is expected to continue in the second half of the year, further impacted by higher silver prices. Reported Earnings • May 16
First quarter 2024 earnings released: €0.11 loss per share (vs €0.14 loss in 1Q 2023) First quarter 2024 results: €0.11 loss per share (improved from €0.14 loss in 1Q 2023). Revenue: €250.0m (down 7.4% from 1Q 2023). Net loss: €16.0m (loss narrowed 24% from 1Q 2023). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 32% per year, which means it has not declined as severely as earnings. New Risk • Apr 11
New major risk - Revenue and earnings growth Earnings have declined by 25% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 25% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.8% average weekly change). Reported Earnings • Mar 14
Full year 2023 earnings released: €0.32 loss per share (vs €1.42 loss in FY 2022) Full year 2023 results: €0.32 loss per share (improved from €1.42 loss in FY 2022). Revenue: €1.15b (down 38% from FY 2022). Net loss: €53.0m (loss narrowed 76% from FY 2022). Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Healthcare Services industry in Europe. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings. Announcement • Mar 14
Agfa-Gevaert NV Reports Impairment Losses on Intangibles and Pp&E for the Fourth Quarter Ended December 31, 2023 Agfa-Gevaert NV reported Impairment losses on intangibles and PP&E for the fourth quarter ended December 31, 2023. For the quarter, the company reported Impairment losses on intangibles and PP&E of €2 million against €29 million a year ago. Announcement • Mar 13
Agfa Appoints Jeroen Spruyt as President of Agfa’s Radiology Solutions Division Agfa announced that Jeroen Spruyt will assume the position of President of Agfa’s Radiology Solutions division. He will also join Agfa’s Executive Management Team. Jeroen Spruyt holds a degree in Applied Economics, complemented by an MBA from Vlerick Business School. Through his career in logistics and his pivotal role as co-founder and board member of TheSignalling Company, Jeroen has demonstrated exceptional leadership acumen and an entrepreneurial mindset. In September 2022, Jeroen joined the Agfa-Gevaert Group as Head of the Direct Radiography (DR) business unit, which is part of the Radiology Solutions division. He will continue to lead the DR business unit alongside his new responsibilities. New Risk • Feb 29
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -€101m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. This is currently the only risk that has been identified for the company. Reported Earnings • Nov 16
Third quarter 2023 earnings released: €0.08 loss per share (vs €0.12 loss in 3Q 2022) Third quarter 2023 results: €0.08 loss per share (improved from €0.12 loss in 3Q 2022). Revenue: €280.0m (down 41% from 3Q 2022). Net loss: €12.0m (loss narrowed 33% from 3Q 2022). Revenue is expected to decline by 5.9% p.a. on average during the next 3 years, while revenues in the Healthcare Services industry in the United Kingdom are expected to grow by 6.1%. Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings. Announcement • Sep 20
Agfa-Gevaert NV to Report Q3, 2023 Results on Nov 15, 2023 Agfa-Gevaert NV announced that they will report Q3, 2023 results at 7:45 AM, Central European Standard Time on Nov 15, 2023 Reported Earnings • Aug 23
Second quarter 2023 earnings released: €0.11 loss per share (vs €0.10 loss in 2Q 2022) Second quarter 2023 results: €0.11 loss per share (further deteriorated from €0.10 loss in 2Q 2022). Revenue: €287.0m (down 39% from 2Q 2022). Net loss: €17.0m (flat on 2Q 2022). Revenue is expected to decline by 5.9% p.a. on average during the next 3 years, while revenues in the Healthcare Services industry in the United Kingdom are expected to grow by 8.1%. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings. Announcement • Jul 25
Agfa-Gevaert NV to Report Q2, 2023 Results on Aug 23, 2023 Agfa-Gevaert NV announced that they will report Q2, 2023 results on Aug 23, 2023 Breakeven Date Change • May 23
Forecast breakeven date pushed back to 2025 The analyst covering Agfa-Gevaert previously expected the company to break even in 2023. New forecast suggests losses will reduce by 85% per year to 2024. The company is expected to make a profit of €3.47m in 2025. Average annual earnings growth of 113% is required to achieve expected profit on schedule. Reported Earnings • May 10
First quarter 2023 earnings released: €0.14 loss per share (vs €0.02 loss in 1Q 2022) First quarter 2023 results: €0.14 loss per share (further deteriorated from €0.02 loss in 1Q 2022). Revenue: €270.0m (down 36% from 1Q 2022). Net loss: €21.0m (loss widened 425% from 1Q 2022). Revenue is expected to decline by 16% p.a. on average during the next 3 years, while revenues in the Healthcare Services industry in the United Kingdom are expected to grow by 10.0%. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings. Reported Earnings • Mar 09
Full year 2022 earnings released: €1.41 loss per share (vs €0.10 loss in FY 2021) Full year 2022 results: €1.41 loss per share (further deteriorated from €0.10 loss in FY 2021). Revenue: €1.86b (up 5.5% from FY 2021). Net loss: €221.0m (loss widened €204.0m from FY 2021). Revenue is expected to decline by 1.0% p.a. on average during the next 2 years, while revenues in the Healthcare Services industry in the United Kingdom are expected to grow by 17%. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Board Change • Feb 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Line De Decker was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 10
Third quarter 2022 earnings released: €0.12 loss per share (vs €0.03 loss in 3Q 2021) Third quarter 2022 results: €0.12 loss per share (further deteriorated from €0.03 loss in 3Q 2021). Revenue: €474.0m (up 8.0% from 3Q 2021). Net loss: €18.0m (loss widened 260% from 3Q 2021). Revenue is forecast to stay flat during the next 3 years compared to a 8.6% growth forecast for the Healthcare Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 24
Second quarter 2022 earnings released: €0.11 loss per share (vs €0.09 profit in 2Q 2021) Second quarter 2022 results: €0.11 loss per share (down from €0.09 profit in 2Q 2021). Revenue: €469.0m (up 6.3% from 2Q 2021). Net loss: €17.0m (down 213% from profit in 2Q 2021). Over the next year, revenue is expected to shrink by 2.0% compared to a 33% growth forecast for the Healthcare Services industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • May 10
First quarter 2022 earnings released: €0.02 loss per share (vs €0.03 loss in 1Q 2021) First quarter 2022 results: €0.02 loss per share (up from €0.03 loss in 1Q 2021). Revenue: €424.0m (up 7.1% from 1Q 2021). Net loss: €4.00m (loss narrowed 20% from 1Q 2021). Over the next year, revenue is expected to shrink by 1.8% compared to a 85% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Reported Earnings • Mar 11
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: €0.11 loss per share (up from €0.63 loss in FY 2020). Revenue: €1.76b (up 3.0% from FY 2020). Net loss: €17.0m (loss narrowed 84% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is expected to shrink by 1.5% compared to a 162% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 8% per year whereas the company’s share price has fallen by 5% per year. Reported Earnings • Nov 10
Third quarter 2021 earnings released: €0.03 loss per share (vs €0.16 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: €439.0m (up 7.1% from 3Q 2020). Net loss: €5.00m (loss narrowed 82% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Breakeven Date Change • Sep 08
Forecast to breakeven in 2022 The 2 analysts covering Agfa-Gevaert expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of €29.4m in 2022. Average annual earnings growth of 157% is required to achieve expected profit on schedule. Reported Earnings • Aug 26
Second quarter 2021 earnings released: EPS €0.09 (vs €0.27 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: €441.0m (up 11% from 2Q 2020). Net income: €15.0m (up €62.0m from 2Q 2020). Profit margin: 3.4% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Breakeven Date Change • Jun 26
Forecast breakeven pushed back to 2022 The 2 analysts covering Agfa-Gevaert previously expected the company to break even in 2021. New consensus forecast suggests losses will reduce by 81% to 2021. The company is expected to make a profit of €29.4m in 2022. Average annual earnings growth of 146% is required to achieve expected profit on schedule. Reported Earnings • May 12
First quarter 2021 earnings released: €0.03 loss per share (vs €0.024 loss in 1Q 2020) The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: €396.0m (down 9.2% from 1Q 2020). Net loss: €5.00m (loss widened 25% from 1Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance. Reported Earnings • Apr 18
Full year 2020 earnings released: €0.63 loss per share (vs €0.53 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €1.71b (down 14% from FY 2019). Net loss: €106.0m (loss widened 19% from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance. Reported Earnings • Mar 12
Full year 2020 earnings released: €0.63 loss per share (vs €0.35 loss in FY 2019) The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €1.71b (down 24% from FY 2019). Net loss: €106.0m (loss widened 83% from FY 2019). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 109 percentage points per year, which is a significant difference in performance. Analyst Estimate Surprise Post Earnings • Mar 12
Revenue beats expectations Revenue exceeded analyst estimates by 0.4%. Over the next year, revenue is forecast to grow 5.9%, compared to a 2,133% growth forecast for the Healthcare Services industry in the United Kingdom. Is New 90 Day High Low • Mar 04
New 90-day low: €3.60 The company is down 3.0% from its price of €3.72 on 04 December 2020. The British market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Healthcare Services industry, which is up 16% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €24.09 per share. Is New 90 Day High Low • Dec 24
New 90-day high: €3.98 The company is up 14% from its price of €3.49 on 25 September 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Healthcare Services industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €26.62 per share. 
